Abeome Announces Collaboration with Medicago to Develop Neutralizing Monoclonal Antibodies for the H5N1 and H1N1 Influenza VLPs
March 2010
Abeome
Corporation, a Georgia-based biotech company, today announced a
collaboration with Medicago Inc. (TSX-V: MDG) to develop neutralizing monoclonal
antibodies to Medicago's H5N1 and H1N1 VLPs using Abeome's
patented DiSH (Direct Selection of Hybridoma) technology.
Click here for additional details.
July 2008
Abeome announced today a strategic equity investment by Cato BioVentures and a research collaboration with Cato Research Ltd., its global contract research organization. Click here for additional details.
Abeome and Millipore launch monoclonal antibody for stem cell research
November 2007
Abeome announced the launch of a unique stem cell monoclonal antibody (mAb) for distribution through Millipore Corporation. Under the agreement, Millipore is granted an exclusive worldwide license to market and distribute the antibody for research use. Abeome has received an upfront payment and will also receive royalties on sales by Millipore. Click here for additional details.
Abeome receives VentureLab Phase IIIa loan from the Georgia Research Alliance
November 2007
Abeome has been awarded a follow-on $80,000 loan from the Georgia Research Alliance (GRA) for Abeome to use to continue the development of its monoclonal antibody technology. In addition, these funds, which have favorable repayment terms, will enable Abeome to expand its presence at trade shows and biotech partnering conferences.
Abeome Announces First-Class Scientific
Advisory Board to Support its Research Activities
September 2008
Abeome Corporation, a Georgia-based biotech company, today
announced the formation of its Scientific Advisory Board (SAB)
to collaborate on the development of Abeome's ovarian cancer
project and to select and guide future therapeutic and
diagnostic projects for the company.
Click here for additional details.
July 2008
Abeome announced today a strategic equity investment by Cato BioVentures and a research collaboration with Cato Research Ltd., its global contract research organization. Click here for additional details.
Abeome and Millipore launch monoclonal antibody for stem cell research
November 2007
Abeome announced the launch of a unique stem cell monoclonal antibody (mAb) for distribution through Millipore Corporation. Under the agreement, Millipore is granted an exclusive worldwide license to market and distribute the antibody for research use. Abeome has received an upfront payment and will also receive royalties on sales by Millipore. Click here for additional details.
Abeome receives VentureLab Phase IIIa loan from the Georgia Research Alliance
November 2007
Abeome has been awarded a follow-on $80,000 loan from the Georgia Research Alliance (GRA) for Abeome to use to continue the development of its monoclonal antibody technology. In addition, these funds, which have favorable repayment terms, will enable Abeome to expand its presence at trade shows and biotech partnering conferences.
Abeome selected to present at the Southeast BIO Investor Forum
September 2007
Abeome was selected as one of 24 emerging biotech firms to present at the Southeast BIO Investor Forum, an event that brings together the Southeast's most promising life science venture opportunities with the regional and national venture capital community. Click here for additional details.
Two biotech execs added to Abeome Board
June 2007
Dr. Kirby Alton, former VP of Research for Amgen and John Richard, former CEO of Impath and current managing partner of GVP, have been elected to the BOD effective 1 June 2007.
Two venture capital firms make initial investment in Abeome
June 2007
Abeome announced that the Georgia Venture Partners and the ATDC Seed Capital Fund have made an equity investment in the company in the total amount of $350k.
Innovation grant for $100K awarded to Abeome for ovarian cancer research
May 2007
Abeome announced that the Georgia Research Alliance (GRA) had awarded the company with a matching grant of $100k to develop monoclonal antibodies and perform functional testing on a several lines of ovarian cancer cells. The project will commence in July and is a collaboration among several top researchers at UGA including Dr. Rich Meagher and Dr. David Puett.
Abeome exhibits at PEGS Conference in Boston, MA
May 2007
The Protein Engineering Summit served as a showcase of Abeome's technology from May 16th through May 18th. The Summit drew scientific experts from around the world and offered a technical dialogue with potential users and licensees of the technology.
Herb Heyneker, Ph.D. joins Abeome Board of Directors
March 2007
Abeome announced that Herb Heyneker, Ph.D., one of the original scientists at Genentech and current executive/consultant for a number of biotech companies around the world, has joined its board of directors. Herb brings astute technology insight and start-up biotech experience to the team.
Novocell (BresaGen) and Abeome announce R&D and Commercialization Agreement
March 2007
Abeome and Novocell, through its BresaGen subsidiary, announced a strategic research and commercialization agreement that partners Novocell's stem cell technologies with Abeome's mAb technology to develop target therapeutic products and reagents for the research tool markets.
Abeome receives VentureLab Phase IIb Grant from the Georgia Research Alliance
February 2007
The Georgia Research Alliance (GRA) announced that it has awarded Abeome a follow on $50,000 grant for Abeome to continue its development of a commercialization model for licensing the DiSH technology. The company will again be working with SSB Solutions, a leading heathcare consulting firm, to create marketing materials and booth graphics for future presentations at technology trade shows.
Abeome presents at North American BioPartnering in Vancouver, BC
Februrary 2007
Abeome presented its technology and business strategy at the 5th Annual BioPartnering Conference. The conference enjoyed its highest attendance ever and provided one-on-one opportunities for Abeome to explore potential licensing deals and technology collaborations with a number of biotech companies.
Abeome key patent is issued in the US
December 2006
The US Patent and Trademark Office issued Abeome's "Rapid Production of Monoclonal Antibodies" (Meagher et al.) patent on 12 December 2006. The patent is held by the University of Georgia Research Foundation (UGARF) and provides intellectual property protection for the company via an exclusive licensing deal with UGARF.
Abeome receives VentureLab Grant from the Georgia Research Alliance
August 2006
Two biotech execs added to Abeome Board
June 2007
Dr. Kirby Alton, former VP of Research for Amgen and John Richard, former CEO of Impath and current managing partner of GVP, have been elected to the BOD effective 1 June 2007.
Two venture capital firms make initial investment in Abeome
June 2007
Abeome announced that the Georgia Venture Partners and the ATDC Seed Capital Fund have made an equity investment in the company in the total amount of $350k.
Innovation grant for $100K awarded to Abeome for ovarian cancer research
May 2007
Abeome announced that the Georgia Research Alliance (GRA) had awarded the company with a matching grant of $100k to develop monoclonal antibodies and perform functional testing on a several lines of ovarian cancer cells. The project will commence in July and is a collaboration among several top researchers at UGA including Dr. Rich Meagher and Dr. David Puett.
Abeome exhibits at PEGS Conference in Boston, MA
May 2007
The Protein Engineering Summit served as a showcase of Abeome's technology from May 16th through May 18th. The Summit drew scientific experts from around the world and offered a technical dialogue with potential users and licensees of the technology.
Herb Heyneker, Ph.D. joins Abeome Board of Directors
March 2007
Abeome announced that Herb Heyneker, Ph.D., one of the original scientists at Genentech and current executive/consultant for a number of biotech companies around the world, has joined its board of directors. Herb brings astute technology insight and start-up biotech experience to the team.
Novocell (BresaGen) and Abeome announce R&D and Commercialization Agreement
March 2007
Abeome and Novocell, through its BresaGen subsidiary, announced a strategic research and commercialization agreement that partners Novocell's stem cell technologies with Abeome's mAb technology to develop target therapeutic products and reagents for the research tool markets.
Abeome receives VentureLab Phase IIb Grant from the Georgia Research Alliance
February 2007
The Georgia Research Alliance (GRA) announced that it has awarded Abeome a follow on $50,000 grant for Abeome to continue its development of a commercialization model for licensing the DiSH technology. The company will again be working with SSB Solutions, a leading heathcare consulting firm, to create marketing materials and booth graphics for future presentations at technology trade shows.
Abeome presents at North American BioPartnering in Vancouver, BC
Februrary 2007
Abeome presented its technology and business strategy at the 5th Annual BioPartnering Conference. The conference enjoyed its highest attendance ever and provided one-on-one opportunities for Abeome to explore potential licensing deals and technology collaborations with a number of biotech companies.
Abeome key patent is issued in the US
December 2006
The US Patent and Trademark Office issued Abeome's "Rapid Production of Monoclonal Antibodies" (Meagher et al.) patent on 12 December 2006. The patent is held by the University of Georgia Research Foundation (UGARF) and provides intellectual property protection for the company via an exclusive licensing deal with UGARF.
Abeome receives VentureLab Grant from the Georgia Research Alliance
August 2006
The Georgia Research Alliance (GRA) announced in August that it has awarded Abeome a $50,000 grant for developing a commercialization model for licensing the DiSH technology. The company will be working with SSB Solutions, a leading heathcare consulting firm, to devise its strategy and update its business plan.
Read our latest press releases
Abeome Announces Collaboration with Medicago
March 2010
Abeome Announces First-Class Scientific Advisory Board to Support its Research Activities
September 2008